Orexigen’s Contrave COR-I Trial Results Published Online in Journal Lancet
Orexigen’s Contrave COR-I trial results published online in journal Lancet
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose …
Read more on News-Medical-Net
Leaders criticized in Army suicides
WASHINGTON – After nine years of war, the Army attracts recruits ready for combat but inclined toward risky personal behavior – a volatile mix that led to more deaths from suicide, drug overdoses and drinking and driving than from warfare, an Army review concludes.
Read more on The Oshkosh Northwestern















































